PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.
Kleineidam L, Chouraki V, Pr?chnicki T, van der Lee SJ, Madrid-M?rquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, Martino Adami PV, Lewczuk P, Popp J, Brosseron F, Jansen IE, Hulsman M, Kornhuber J, Peters O, Berr C, Heun R, Fr?lich L, Tzourio C, Dartigues JF, H?ll M, Espinosa A, Hern?ndez I, de Rojas I, Orellana A, Valero S, Stringa N, van Schoor NM, Huisman M, Scheltens P, R?ther E, Deleuze JF, Wiltfang J, Tarraga L, Schmid M, Scherer M, Riedel-Heller S, Heneka MT, Amouyel P, Jessen F, Boada M, Maier W, Schneider A, Gonz?lez-P?rez A, van der Flier WM, Wagner M, Lambert JC, Holstege H, S?ez ME, Latz E, Ruiz A, Ramirez A. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 2020 06; 139(6):1025-1044.